-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compileriver
In December last year, the FDA rejected Novartis’ siRNA cholesterol-lowering drug Leqvio (inclisiran) due to the inability to complete the production site inspection on time
Leqvio is an interfering RNA (siRNA) drug targeting PCSK9.
Leqvio is a core product that Novartis acquired from Medicines Pharmaceuticals at a cost of US$9.
In addition to rejections related to production verification, the new crown pandemic has also affected an important trial of the drug
Currently, Leqvio's data can only show that it can reduce harmful cholesterol levels
Novartis launched Leqvio in Germany and Austria in February this year for patients with extremely high cardiovascular risk
Reference source: Novartis revives inclisiran US filing by sidestepping FDA's manufacturing inspection concerns